FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...
Get the latest industry news, event updates and more from Managed Healthcare Executive.
Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation. Balancing innovation and ...
Reconstructed IPD meta-analysis showed chemoimmunotherapy improved OS and PFS versus PD-(L)1 monotherapy within PD-L1–high disease, with consistent findings across multiple analytic approaches and ...
This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to ...
This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable ...
In SYNCHRONIZE-MASLD (n=218), 84.2% on weekly survodutide 6.0 mg achieved ≥30% relative liver fat reduction versus 24.3% with placebo at week 48. Liver fat normalization occurred in ~61% of ...
Sponsored by Esperion. Newsletter Get the latest industry news, event updates and more from Managed Healthcare Executive.
Cohorts included 1,653 AL, 1,055 ATTRwt-CM, and 59 dual-diagnosis patients; only 53%–66% had any relevant test documented, and just 40%–49% had AL-specific workups. Complete monoclonal protein testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results